Rigel Pharmaceuticals (RIGL) Non-Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $270.6 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 820.06% year-over-year to $270.6 million; the TTM figure through Mar 2026 stood at $603.0 million (up 382.68% YoY), while the FY2025 annual figure was $273.4 million, up 847.0% from the prior year.
• Non-Current Assets was $270.6 million for Q1 2026 at Rigel Pharmaceuticals, down from $273.4 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $273.4 million in Q4 2025 to a low of $5.2 million in Q3 2022.
• Historically, Non-Current Assets has averaged $51.4 million across 5 years, with a median of $27.6 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets tumbled 66.47% in 2022, then surged 847.0% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $18.4 million in 2022, then declined by 2.27% to $18.0 million in 2023, then surged by 60.77% to $28.9 million in 2024, then soared by 847.0% to $273.4 million in 2025, then dropped by 1.04% to $270.6 million in 2026.
• The last three Non-Current Assets figures came in at $270.6 million (Q1 2026), $273.4 million (Q4 2025), and $27.6 million (Q3 2025), per Business Quant data.